Gene fusion - Revision history

Jensflorian: +cat

2018-10-04T08:23:50Z

+cat

← Older revision		Revision as of 08:23, 4 October 2018
Line 23:		Line 23:
	* NAB2-STAT6 fusion in [[Solitary fibrous tumour]].		* NAB2-STAT6 fusion in [[Solitary fibrous tumour]].
	* RELA fusion in supratentorial [[ependymoma]] (up to 70% in children).		* RELA fusion in supratentorial [[ependymoma]] (up to 70% in children).

			==See also==
			*[[Molecular pathology]].
			*[[Oncogene]].


			[[Category:Molecular pathology]]

2018-10-04T08:21:58Z

+examples

← Older revision		Revision as of 08:21, 4 October 2018
Line 17:		Line 17:
	* Whole Genome sequencing (WGS) (Comprehensive and unbiased, but short read length).		* Whole Genome sequencing (WGS) (Comprehensive and unbiased, but short read length).
	* [[Immunohistochemistry]] (not suitable/available for all fusions).		* [[Immunohistochemistry]] (not suitable/available for all fusions).

			==Examples==
			Common fusion in [[Neuropathology]]:
			* KIAA1549-BRAF fusion in [[pilocytic astrocytoma]] (up to 70%).
			* NAB2-STAT6 fusion in [[Solitary fibrous tumour]].
			* RELA fusion in supratentorial [[ependymoma]] (up to 70% in children).

2018-10-04T08:18:52Z

← Older revision		Revision as of 08:18, 4 October 2018
Line 9:		Line 9:

	First fusion was described as BCR-ABL1 fusion in [[CML]]. Subsequently [[Imatinib]] was the first inhibitor targeting CML with BCR-ABL1 fusion.		First fusion was described as BCR-ABL1 fusion in [[CML]]. Subsequently [[Imatinib]] was the first inhibitor targeting CML with BCR-ABL1 fusion.

			==Methodology==
			Gene fusions can be detected by:
			* [[RT-PCR]] (fusion partners need to be known).
			* [[FISH]].
			* RNA-Sequencing.
			* Whole Genome sequencing (WGS) (Comprehensive and unbiased, but short read length).
			* [[Immunohistochemistry]] (not suitable/available for all fusions).

2018-10-04T08:13:38Z

history

← Older revision		Revision as of 08:13, 4 October 2018
Line 7:		Line 7:
	* duplication.		* duplication.
	* inversion.		* inversion.

			First fusion was described as BCR-ABL1 fusion in [[CML]]. Subsequently [[Imatinib]] was the first inhibitor targeting CML with BCR-ABL1 fusion.

2018-10-04T08:09:11Z

+general

← Older revision		Revision as of 08:09, 4 October 2018
Line 1:		Line 1:
	'''Gene fusion''' is a common event in cancer. It is hybrid of two coding or regulatory DNA sequences.		'''Gene fusion''' is a common event in cancer and a re-occuring theme in [[molecular pathology]]. It is hybrid of two coding or regulatory DNA sequences.

			==General==
			Caused by genomic rearrangements such as:
			* translocation.
			* deletion.
			* duplication.
			* inversion.

2018-10-04T08:05:53Z

init

New page

'''Gene fusion''' is a common event in cancer. It is hybrid of two coding or regulatory DNA sequences.